Sanofi's SAR446523 gains FDA orphan drug status, offering hope for relapsed multiple myeloma patients with its targeted ...

SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status and is in phase 1 trials for ...

Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma Designation granted for IgG1-based GPRC5D monoclonal antibody for the potential treatment ...

FDA granted Orphan Drug Designation to Sanofi’s SAR446523, a monoclonal antibody targeting GPRC5D, for relapsed/refractory ...

G protein-coupled receptor, class C, group 5, member D (GPRC5D) loss after chimeric antigen receptor (CAR) T-cell therapy in ...

“The study confirms GPRC5D as a viable target in multiple myeloma,” said Eric Smith, M.D., Ph.D., a medical oncologist and the Director of Clinical Translation within the Cellular Therapeutics ...

DelveInsight's GPRC5D-directed Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices ...

VIDEO: Role of targeting GPRC5D in multiple myelomaSession ID: 2025-04-20:56b9b4514f53b3d652d47c96 Player Element ID: V77fb78de_6eb7_4a8f_b2c2_64afef5f89da_6357257240112 ...

Beyond this patient, we identified that relapses after GPRC5D-directed CAR T-cell therapy were associated with decreased or no expression of GPRC5D messenger RNA (mRNA) (Figure 1F and Fig. S2 and ...

GPRC5D-directed Therapies Epidemiology Segmentation The GPRC5D-directed therapies market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: ...

US FDA grants orphan drug designation to Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns to treat multiple myeloma: Paris Friday, August 1, 2025, 09:00 Hrs [IST] The US ...